Loading
Nanoplatforms for Cancer Theranostics · Journal article
Journal of Food and Drug Analysis · July 22, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing emerging preclinical and mechanistic approaches to antifungal therapy against Candida albicans, including metal–organic frameworks, host-directed therapies, CRISPR-Cas9 gene editing, and phytochemicals. The review identifies conceptual opportunities and challenges but does not present clinical trial evidence, efficacy comparisons, or outcome data in humans.
Narrative literature review. Candida albicans infections in immunocompromised hosts and mucosal disease contexts..
Metal–organic frameworks offer high drug-loading capacity, controlled release, and enhanced penetration into biofilms, with promise against drug-resistant strains. Selected phytochemicals demonstrate inhibitory effects on virulence traits including hyphal formation and enzyme secretion. CRISPR-Cas9 enables functional genomic studies to identify and disrupt key pathogenicity genes.
Preclinical findings (MOFs, CRISPR, phytochemicals) lack human safety and efficacy data.
This review identifies promising mechanistic directions but does not provide evidence sufficient to guide current clinical practice. Clinicians should view these strategies as exploratory research avenues, not yet validated for patient care.
A narrative review of emerging preclinical and mechanistic strategies against Candida albicans, lacking clinical trial data, hard outcomes, or comparative efficacy evidence.
As stated by the source record.
This review identifies promising mechanistic directions but does not provide evidence sufficient to guide current clinical practice. Clinicians should view these strategies as exploratory research avenues, not yet validated for patient care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Candida albicans is an opportunistic fungal pathogen responsible for infections ranging from superficial mucosal disease to life-threatening systemic candidiasis, particularly in immunocompromised hosts. Its pathogenicity is enhanced by morphological plasticity, biofilm formation, and immune evasion, contributing to antifungal resistance. Limitations of existing antifungals have driven interest in emerging therapeutics. This review highlights strategies including metal–organic frameworks (MOFs), host-directed therapies (HDTs), CRISPR-Cas9 gene editing, and phytochemicals. MOFs offer high drug-loading capacity, controlled release, and enhanced penetration into biofilms, showing promise against drug-resistant strains. Selected phytochemicals demonstrate inhibitory effects on virulence traits such as hyphal formation and enzyme secretion. CRISPR-Cas9 enables functional genomic studies to identify and disrupt key pathogenicity genes, while HDTs aim to boost host immune responses. Additionally, the potential role of gut microbiota modulation in controlling C. albicans colonization is discussed. By integrating mechanistic insights with translational perspectives, this review provides a concise overview of emerging antifungal strategies, opportunities, and challenges with the potential to overcome current therapeutic limitations
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.